AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.22 Billion INR | -23.05% |
| 2022 | 5.77 Billion INR | 28.91% |
| 2021 | 4.48 Billion INR | -6.25% |
| 2020 | 4.78 Billion INR | -3.9% |
| 2019 | 4.97 Billion INR | 13.74% |
| 2018 | 4.37 Billion INR | 25.86% |
| 2017 | 3.47 Billion INR | 1.72% |
| 2016 | 3.41 Billion INR | -2.67% |
| 2015 | 3.5 Billion INR | 31.88% |
| 2014 | 2.66 Billion INR | -9.37% |
| 2013 | 2.93 Billion INR | 35.59% |
| 2012 | 2.16 Billion INR | -35.42% |
| 2011 | 3.35 Billion INR | -17.83% |
| 2010 | 4.08 Billion INR | 56.7% |
| 2009 | 2.6 Billion INR | 10.35% |
| 2008 | 2.35 Billion INR | 18.65% |
| 2007 | 1.98 Billion INR | 18.08% |
| 2006 | 1.68 Billion INR | -24.27% |
| 2005 | 2.22 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 922.1 Million INR | -14.55% |
| 2023 Q2 | 1.88 Billion INR | 2.2% |
| 2023 Q1 | 1.84 Billion INR | 53.06% |
| 2023 Q4 | 1.07 Billion INR | -31.49% |
| 2023 Q3 | 1.57 Billion INR | -16.64% |
| 2023 FY | 4.44 Billion INR | -23.05% |
| 2022 Q3 | 1.58 Billion INR | 5.83% |
| 2022 Q4 | 1.2 Billion INR | -23.72% |
| 2022 Q1 | 1.48 Billion INR | 50.63% |
| 2022 Q2 | 1.49 Billion INR | 0.45% |
| 2022 FY | 5.77 Billion INR | 28.91% |
| 2021 Q3 | 1.22 Billion INR | 4.61% |
| 2021 Q4 | 988.86 Million INR | -19.52% |
| 2021 FY | 4.48 Billion INR | -6.25% |
| 2021 Q1 | 1.08 Billion INR | 16.97% |
| 2021 Q2 | 1.17 Billion INR | 7.82% |
| 2020 Q2 | 1.31 Billion INR | 9.01% |
| 2020 FY | 4.78 Billion INR | -3.9% |
| 2020 Q4 | 931.31 Million INR | -29.42% |
| 2020 Q3 | 1.31 Billion INR | 0.02% |
| 2020 Q1 | 1.21 Billion INR | 40.71% |
| 2019 Q1 | 1.34 Billion INR | 46.84% |
| 2019 Q2 | 1.34 Billion INR | -0.14% |
| 2019 Q3 | 1.42 Billion INR | 6.12% |
| 2019 Q4 | 860.04 Million INR | -39.67% |
| 2019 FY | 4.97 Billion INR | 13.74% |
| 2018 FY | 4.37 Billion INR | 25.86% |
| 2018 Q3 | 1.51 Billion INR | 38.01% |
| 2018 Q4 | 916.14 Million INR | -39.4% |
| 2018 Q1 | 1.09 Billion INR | 2.21% |
| 2018 Q2 | 1.09 Billion INR | 0.46% |
| 2017 Q4 | 1.06 Billion INR | 18.4% |
| 2017 Q3 | 900.95 Million INR | -18.69% |
| 2017 Q2 | 1.1 Billion INR | 34.58% |
| 2017 Q1 | 823.35 Million INR | 6.1% |
| 2017 FY | 3.47 Billion INR | 1.72% |
| 2016 Q2 | 939.41 Million INR | -1.03% |
| 2016 Q4 | 776.02 Million INR | -24.87% |
| 2016 Q3 | 1.03 Billion INR | 9.95% |
| 2016 FY | 3.41 Billion INR | -2.67% |
| 2016 Q1 | 949.23 Million INR | 39.43% |
| 2015 FY | 3.5 Billion INR | 31.88% |
| 2015 Q4 | 680.79 Million INR | -24.77% |
| 2015 Q3 | 904.92 Million INR | 11.06% |
| 2015 Q2 | 814.82 Million INR | 10.71% |
| 2015 Q1 | 735.98 Million INR | 16.22% |
| 2014 Q4 | 633.28 Million INR | -8.72% |
| 2014 FY | 2.66 Billion INR | -9.37% |
| 2014 Q1 | 718.73 Million INR | 29.86% |
| 2014 Q2 | 615.13 Million INR | -14.41% |
| 2014 Q3 | 693.81 Million INR | 12.79% |
| 2013 Q4 | 553.46 Million INR | -30.92% |
| 2013 FY | 2.93 Billion INR | 35.59% |
| 2013 Q1 | 818 Million INR | 89.96% |
| 2013 Q2 | 763.23 Million INR | -6.7% |
| 2013 Q3 | 801.23 Million INR | 4.98% |
| 2012 Q3 | 645.21 Million INR | 16.24% |
| 2012 Q2 | 555.06 Million INR | 4.05% |
| 2012 Q1 | 533.44 Million INR | 34.59% |
| 2012 FY | 2.16 Billion INR | -35.42% |
| 2012 Q4 | 430.62 Million INR | -33.26% |
| 2011 Q4 | 396.35 Million INR | -62.69% |
| 2011 Q3 | 1.06 Billion INR | 0.0% |
| 2011 FY | 3.35 Billion INR | -17.83% |
| 2010 FY | 4.08 Billion INR | 56.7% |
| 2009 FY | 2.6 Billion INR | 10.35% |
| 2008 FY | 2.35 Billion INR | 18.65% |
| 2007 FY | 1.98 Billion INR | 18.08% |
| 2006 FY | 1.68 Billion INR | -24.27% |
| 2005 FY | 2.22 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 76.764% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 95.977% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 49.95% |
| Granules India Limited | 16.79 Billion INR | 62.959% |
| Indoco Remedies Limited | 6.04 Billion INR | -3.002% |
| Achyut Healthcare Limited | 4.86 Million INR | -127912.755% |
| Ajanta Pharma Limited | 21.06 Billion INR | 70.458% |
| Alkem Laboratories Limited | 52.29 Billion INR | 88.101% |
| Alpa Laboratories Limited | 188.89 Million INR | -3194.264% |
| Brooks Laboratories Limited | 65.62 Million INR | -9382.932% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -322.793% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -68.389% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 96.197% |
| Eris Lifesciences Limited | 10.42 Billion INR | 40.32% |
| FDC Limited | 8.33 Billion INR | 25.34% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 91.026% |
| Gufic Biosciences Limited | 4.16 Billion INR | -49.308% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -0.458% |
| Ipca Laboratories Limited | 29.8 Billion INR | 79.125% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -853.539% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -3128.764% |
| Lasa Supergenerics Limited | 121.02 Million INR | -5041.453% |
| Laurus Labs Limited | 24.62 Billion INR | 74.725% |
| Lupin Limited | 123.71 Billion INR | 94.97% |
| Mankind Pharma Limited | 44.52 Billion INR | 86.023% |
| Medicamen Biotech Limited | 495.49 Million INR | -1155.855% |
| Medico Remedies Limited | 262.14 Million INR | -2273.772% |
| Megasoft Limited | 342.07 Million INR | -1719.125% |
| NATCO Pharma Limited | 25.73 Billion INR | 75.821% |
| Piramal Pharma Limited | 24.47 Billion INR | 74.571% |
| RPG Life Sciences Limited | 2.48 Billion INR | -150.612% |
| Sigachi Industries Limited | 2 Billion INR | -210.78% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 97.593% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -50.916% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -560.304% |
| Unichem Laboratories Limited | 4.86 Billion INR | -27.909% |
| Wanbury Limited | 1.73 Billion INR | -259.56% |
| Windlas Biotech Limited | 1.33 Billion INR | -364.797% |
| ZIM Laboratories Limited | 1.26 Billion INR | -391.18% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 95.03% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1132.974% |
| Divi's Laboratories Limited | 32.44 Billion INR | 80.818% |
| Hester Biosciences Limited | 1.27 Billion INR | -388.572% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -7.633% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -299.78% |
| Bal Pharma Limited | 770.19 Million INR | -707.938% |
| Strides Pharma Science Limited | 14.38 Billion INR | 56.751% |
| Venus Remedies Limited | 2.18 Billion INR | -185.107% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -6.711% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -109.373% |
| Shilpa Medicare Limited | 3.54 Billion INR | -75.442% |
| Aarti Drugs Limited | 8.31 Billion INR | 25.174% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -35.843% |
| Suven Life Sciences Limited | -200.79 Million INR | 3199.0% |
| Ind-Swift Limited | 2.17 Billion INR | -186.426% |
| Valiant Laboratories Limited | -60.66 Million INR | 10357.649% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 72.587% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -622.562% |
| Themis Medicare Limited | 1.5 Billion INR | -313.77% |
| Hikal Limited | 3.14 Billion INR | -97.981% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 86.691% |
| Sequent Scientific Limited | 2.97 Billion INR | -108.904% |
| Novartis India Limited | 1.32 Billion INR | -368.965% |
| Wockhardt Limited | 16.24 Billion INR | 61.683% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 68.321% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -42580.576% |
| Neuland Laboratories Limited | 8.24 Billion INR | 24.554% |
| Morepen Laboratories Limited | 6.16 Billion INR | -0.997% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -902.89% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -784.402% |